Scholarlink

Background <p>Migraine is a complex neurological disorder characterized by recurrent, disabling headaches and various sensory symptoms, affecting about 15% of the global population annually. It is the second most common neurological condition worldwide, causing significant disability. While current prophylactic treatments include beta-blockers, tricyclic antidepressants, anticonvulsants, and monoclonal antibodies targeting the CGRP pathway, not all patients respond adequately. Atogepant, an oral CGRP receptor antagonist, has emerged as a promising option for migraine prevention with improved tolerability.</p> Methods <p>This meta-analysis follows PRISMA guidelines, involving a comprehensive search of Cochrane CENTRAL, PubMed/MEDLINE, and Google Scholar databases up to July 2024. Efficacy outcomes included mean monthly migraine days (MMDs), mean monthly headache days (MHDs), monthly acute medication use days and the percentage of patients with a ≥ 50% reduction in MMDs. Safety outcomes were measured by adverse events (AEs). Statistical analysis employed the Inverse Variance and Mantel-Haenszel random-effects models, with heterogeneity assessed using the I² index.</p> Results <p>Six RCTs with 4325 patients (3054 on Atogepant, 1271 on placebo) met the inclusion criteria. The combined analysis indicated a significant reduction in MMDs favoring Atogepant over placebo (SMD − 0.39, 95% CI: -0.45 to -0.33; <i>p</i> &lt; 0.00001; I²=0%). Similarly, significant reductions were observed in MHDs, monthly acute medication use days, and the proportion of patients achieving a ≥ 50% reduction in MMDs.</p> Conclusion <p>Atogepant is an effective and safe option for migraine prophylaxis, showing significant reductions in MMDs. Further extensive trials are recommended to assess the long-term efficacy, safety, and cost efficiency of Atogepant compared to other preventive medications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

“The efficacy and safety of Atogepant for migraine prophylaxis: a systematic review and meta-analysis of randomized controlled trials”

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月9日

查看全文
  • Ayesha Shaukat,
  • Laiba Shakeel,
  • Rumaisa Riaz,
  • Saad Ashraf,
  • Aymar Akilimali

摘要

Background

Migraine is a complex neurological disorder characterized by recurrent, disabling headaches and various sensory symptoms, affecting about 15% of the global population annually. It is the second most common neurological condition worldwide, causing significant disability. While current prophylactic treatments include beta-blockers, tricyclic antidepressants, anticonvulsants, and monoclonal antibodies targeting the CGRP pathway, not all patients respond adequately. Atogepant, an oral CGRP receptor antagonist, has emerged as a promising option for migraine prevention with improved tolerability.

Methods

This meta-analysis follows PRISMA guidelines, involving a comprehensive search of Cochrane CENTRAL, PubMed/MEDLINE, and Google Scholar databases up to July 2024. Efficacy outcomes included mean monthly migraine days (MMDs), mean monthly headache days (MHDs), monthly acute medication use days and the percentage of patients with a ≥ 50% reduction in MMDs. Safety outcomes were measured by adverse events (AEs). Statistical analysis employed the Inverse Variance and Mantel-Haenszel random-effects models, with heterogeneity assessed using the I² index.

Results

Six RCTs with 4325 patients (3054 on Atogepant, 1271 on placebo) met the inclusion criteria. The combined analysis indicated a significant reduction in MMDs favoring Atogepant over placebo (SMD − 0.39, 95% CI: -0.45 to -0.33; p < 0.00001; I²=0%). Similarly, significant reductions were observed in MHDs, monthly acute medication use days, and the proportion of patients achieving a ≥ 50% reduction in MMDs.

Conclusion

Atogepant is an effective and safe option for migraine prophylaxis, showing significant reductions in MMDs. Further extensive trials are recommended to assess the long-term efficacy, safety, and cost efficiency of Atogepant compared to other preventive medications.